Restoring BalanceAt Aldeyra, we’re a pioneer in the development of medicines to improve the lives of patients with immune-mediated diseases. Our pipeline of drug candidates is focused on inhibiting inflammatory cells linked to ocular and systemic conditions not adequately addressed by current treatments. By developing and commercializing these next-generation therapies, we have one goal: to help patients lead healthier lives.
At Aldeyra, we’re a pioneer in the development of medicines to improve the lives of patients with immune-mediated diseases. Our pipeline of drug candidates is focused on inhibiting inflammatory cells linked to ocular and systemic conditions not adequately addressed by current treatments. By developing and commercializing these next-generation therapies, we have one goal: to help patients lead healthier lives.
Our Mission
Patients Like Daniele Are the Reason We’re Developing Next-generation Medicines
With investigational therapies in Phase 3 trials for dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy (PVR), we continue to advance toward our goal of bringing to market novel medicines for immune-mediated conditions not adequately addressed by current treatments.
Learn More 
Our Science
Restoring Balance Utilizing Novel Mechanisms of Action
An estimated 7% of western society suffers from some form of immune-mediated disease. At Aldeyra, we are building a proprietary pipeline focused on compounds with distinct mechanisms of action that target immune-mediated ocular diseases and select systemic conditions.
Learn More 
Therapeutic Focus
Targeting Immune-Mediated Diseases with High Unmet Need
We’re developing therapies for the treatment of dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy.
Read More About Ocular Disease TreatmentPipeline
